Cargando…

Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways

In view of an efficient use of the Italian National Health Service-funded healthcare resources, a novel data-processing strategy combining information from multiple sources was developed in a regional cancer network of northern Italy. The goal was to calculate the annual overall cost of care pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Altini, Mattia, Solinas, Laura, Bucchi, Lauro, Gentili, Nicola, Gallegati, Davide, Balzi, William, Falcini, Fabio, Massa, Ilaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369964/
https://www.ncbi.nlm.nih.gov/pubmed/32630745
http://dx.doi.org/10.3390/ijerph17134765
_version_ 1783560890850738176
author Altini, Mattia
Solinas, Laura
Bucchi, Lauro
Gentili, Nicola
Gallegati, Davide
Balzi, William
Falcini, Fabio
Massa, Ilaria
author_facet Altini, Mattia
Solinas, Laura
Bucchi, Lauro
Gentili, Nicola
Gallegati, Davide
Balzi, William
Falcini, Fabio
Massa, Ilaria
author_sort Altini, Mattia
collection PubMed
description In view of an efficient use of the Italian National Health Service-funded healthcare resources, a novel data-processing strategy combining information from multiple sources was developed in a regional cancer network of northern Italy. The goal was to calculate the annual overall cost of care pathways of six disease groups in 10,486 patients. The evaluation was conceived as a population-based cost description from the perspective of the Italian National Health Service. Costs occurred during a defined time period for a cross-section of patients at varying stages of their disease were measured. The total cancer care cost was €81,170,121 (11.1% of total local health expenditure), with a cost per patient of €7741.17 and a cost per capita of €204.62. Surgical, inpatient and day-hospital medical admissions, radiotherapy, drugs, outpatient care, emergency admissions, and home and hospice care accounted for 21.2%, 24.1%, 6.2%, 28.2%, 14.0%, 0.9%, and 5.4% of the total cost, respectively. The highest cost items included drugs (cost per capita, €22.95; 11.2% of total cost) and medical admissions (€14.51; 7.1%) for blood cancer, and surgical (€14.56; 7.1%) and medical admissions (€13.60; 6.6%) for gastrointestinal cancer. The information extracted allows multidisciplinary cancer care teams to be more aware of the costs of their clinical decisions.
format Online
Article
Text
id pubmed-7369964
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73699642020-07-21 Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways Altini, Mattia Solinas, Laura Bucchi, Lauro Gentili, Nicola Gallegati, Davide Balzi, William Falcini, Fabio Massa, Ilaria Int J Environ Res Public Health Article In view of an efficient use of the Italian National Health Service-funded healthcare resources, a novel data-processing strategy combining information from multiple sources was developed in a regional cancer network of northern Italy. The goal was to calculate the annual overall cost of care pathways of six disease groups in 10,486 patients. The evaluation was conceived as a population-based cost description from the perspective of the Italian National Health Service. Costs occurred during a defined time period for a cross-section of patients at varying stages of their disease were measured. The total cancer care cost was €81,170,121 (11.1% of total local health expenditure), with a cost per patient of €7741.17 and a cost per capita of €204.62. Surgical, inpatient and day-hospital medical admissions, radiotherapy, drugs, outpatient care, emergency admissions, and home and hospice care accounted for 21.2%, 24.1%, 6.2%, 28.2%, 14.0%, 0.9%, and 5.4% of the total cost, respectively. The highest cost items included drugs (cost per capita, €22.95; 11.2% of total cost) and medical admissions (€14.51; 7.1%) for blood cancer, and surgical (€14.56; 7.1%) and medical admissions (€13.60; 6.6%) for gastrointestinal cancer. The information extracted allows multidisciplinary cancer care teams to be more aware of the costs of their clinical decisions. MDPI 2020-07-02 2020-07 /pmc/articles/PMC7369964/ /pubmed/32630745 http://dx.doi.org/10.3390/ijerph17134765 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Altini, Mattia
Solinas, Laura
Bucchi, Lauro
Gentili, Nicola
Gallegati, Davide
Balzi, William
Falcini, Fabio
Massa, Ilaria
Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways
title Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways
title_full Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways
title_fullStr Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways
title_full_unstemmed Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways
title_short Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways
title_sort assessment of cancer care costs in disease-specific cancer care pathways
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369964/
https://www.ncbi.nlm.nih.gov/pubmed/32630745
http://dx.doi.org/10.3390/ijerph17134765
work_keys_str_mv AT altinimattia assessmentofcancercarecostsindiseasespecificcancercarepathways
AT solinaslaura assessmentofcancercarecostsindiseasespecificcancercarepathways
AT bucchilauro assessmentofcancercarecostsindiseasespecificcancercarepathways
AT gentilinicola assessmentofcancercarecostsindiseasespecificcancercarepathways
AT gallegatidavide assessmentofcancercarecostsindiseasespecificcancercarepathways
AT balziwilliam assessmentofcancercarecostsindiseasespecificcancercarepathways
AT falcinifabio assessmentofcancercarecostsindiseasespecificcancercarepathways
AT massailaria assessmentofcancercarecostsindiseasespecificcancercarepathways